Author, study (ref.) | Patients (n) | SBRT dose (Gy/fraction) | CT gemcitabina-based | FFLP (%) | PFS (months) | OS (months) | GI toxicity ( ≥ G2) (%) |
---|---|---|---|---|---|---|---|
Koong[12] | 15 | 15–25 Gy/1fx | no | 77% | 2 | 11 from diagnosis | none |
Hoyer[13] | 22 | 45 Gy/3fx | no | 57% | 4.8 | 5.7 from diagnosis | 18% |
Schellenberg[14] | 16 | 25 Gy/1fx | sequential chemotherapy | 81% | 9 | 11.4 from diagnosis | 47% |
Chang[15] | 77 | 25 Gy/ 1fx | For same patients prior CT | 84% | - | 11.4 from diagnosis | 13% |
Schellenberg[16] | 20 | 25 Gy/1fx | sequential chemotherapy | 94% | 9.2 | 11.8 from diagnosis | 20% |
Polistina[17] | 33 | 30 Gy/3fx | Prior chemotherapy | 82.6% | 7.3 | 10.6 | none |
Didolkar[18] | 85 | 15–30 Gy/3 fx | sequential chemotherapy | 91.7% | - | 18.6 from diagnosis 8.6 from SBRT | 22% |
Mahadevan[19] | 39 | 24-36 Gy/3fx | sequential chemotherapy | 85% | 15 from diagnosis | 20 from diagnosis | 9% |
Rwigema[20] | 71 | 18–25 Gy/1fx | no | 64.8% | - | 10.3 | 10% |
Present study | 30 | 36-45Gy/6 fx | Prior chemotherapy | 85% (96% for group of 45 Gy) | 8 from SBRT 14 from diagnosis | 11 from SBRT 19.5 from diagnosis | none |